Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 19/20 | 0.53 |
| ▸ | ABL1 | P00519 | 6/20 | 0.52 |
| ▸ | EGFR | P00533 | 6/20 | 0.52 |
| ▸ | ABL2 | P42684 | 6/20 | 0.52 |
| ▸ | CDK1 | P06493 | 2/20 | 0.52 |
| ▸ | PI4KA | P42356 | 1/20 | 0.48 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.48 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.48 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8820820 | 0.93 | SRC (0.48) | SRCABL1EGFRABL2CDK1 | |
| SCHEMBL8820786 | 0.92 | SRC (0.65) | SRCABL1EGFRABL2CDK1 | |
| SCHEMBL8820855 | 0.91 | SRC (0.53) | SRCABL1EGFRABL2CDK1 | |
| SCHEMBL8820532 | 0.87 | SRC (0.50) | SRCABL1EGFRABL2CDK1 | |
| SCHEMBL8819623 | 0.87 | SRC (0.61) | SRCABL1EGFRABL2CDK1 | |
| SCHEMBL6041054 | 0.85 | SRC (0.67) | SRCABL1EGFRABL2CDK1 | |
| SCHEMBL8820776 | 0.83 | SRC (0.48) | SRCABL1EGFRABL2CDK1 | |
| SCHEMBL8820539 | 0.82 | SRC (0.50) | SRCABL1EGFRABL2CDK1 | |
| SCHEMBL8820771 | 0.80 | SRC (0.49) | SRCABL1EGFRABL2CDK1 | |
| SCHEMBL7842849 | 0.80 | SRC (0.73) | SRCABL1EGFRABL2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1997049706-A1 | SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF | NOVARTIS AG (CH) | 1997-12-31 | — | — | WO | disclosed |